Jefferies analyst Roger Song initiated coverage of Gyre Therapeutics (GYRE) with a Buy rating and $16 price target Gyre is a global commercial biotech with expanding China sales that will supporting pipeline progress, the analyst tells investors in a research note. The firm says the company’s lead asset hydronidone’s Phase 3 study in fibrosis regression in chronic hepatitis B likely supports a first-in-class launch in China in 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Gyre Therapeutics Announces Positive Phase 3 Results
- Gyre Therapeutics: A Compelling Buy with Potential Blockbuster Drug Hydronidone Targeting Liver Fibrosis
- Gyre Therapeutics initiated with a Buy at H.C. Wainwright
- Gyre Therapeutics Appoints Dan Weng to Board
- Gyre Therapeutics appoints Dan Weng to board of directors